Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | BID | P55957 | 1/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449171 | 1.00 | BCL2A1 (0.46) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6431436 | 0.90 | BCL2A1 (0.46) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6431435 | 0.90 | BCL2A1 (0.46) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6431417 | 0.89 | BCL2A1 (0.44) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6431421 | 0.89 | BCL2A1 (0.44) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL5606026 | 0.84 | BCL2A1 (0.46) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL5606021 | 0.84 | BCL2A1 (0.46) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6432500 | 0.83 | BCL2A1 (0.43) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL6432501 | 0.83 | BCL2A1 (0.43) | BCL2A1ALDH1A1LMNABCL2MAPT | |
| SCHEMBL5606554 | 0.82 | BCL2A1 (0.44) | BCL2A1ALDH1A1LMNABCL2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-0894085-B1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6924289-B2 | Benzyl(Idene)-lactam derivatives, their preparation and their use as selective (ANT) agonists of 5-HT1A- and/or 5-HT1D receptors | PFIZER INC (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030027812-A1 | Benzyl(idene)-lactam derivatives, their preperation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462048-B2 | 3-(2-(4-METHYLPIPERAZIN-1-YL)-BENZYLIDENE)-1,3-DIHYDRO-INDOL-2-ONE FOR EXAMPLE; USEFUL AS PSYCHOTHERAPEUTIC AGENTS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027812-A1 | Benzyl(idene)-lactam derivatives, their preperation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors | HTR1A, HTR1E, HTR1D | BCL2A1 881/4885ALDH1A1 1595/4885LMNA 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.